Juan F Navarro-Gonzlez

List of Publications by Citations

163 papers	6,339 citations	42 h-index	76 g-index
196 ext. papers	7,479 ext. citations	4.9 avg, IF	5.88 L-index

#	Paper	IF	Citations
163	Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. *Nature Reviews Nephrology*, **2011**, 7, 327-40	14.9	644
162	The role of inflammatory cytokines in diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 433-42	12.7	623
161	Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. *Journal of the American Society of Nephrology: JASN*, **2015**, 26, 220-9	12.7	351
160	Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. *American Journal of Kidney Diseases*, **2003**, 42, 53-61	7.4	181
159	Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. *American Journal of Nephrology*, **2006**, 26, 562-70	4.6	169
158	Inflammatory cytokines in diabetic nephropathy. *Journal of Diabetes Research*, **2015**, 2015, 948417	3.9	149
157	Inflammation and diabetic nephropathy. *Current Diabetes Reports*, **2006**, 6, 463-8	5.6	144
156	Pathogenic perspectives for the role of inflammation in diabetic nephropathy. *Clinical Science*, **2009** , 116, 479-92	6.5	140
155	The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications. *Cytokine and Growth Factor Reviews*, **2006**, 17, 441-50	17.9	140
154	Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. *American Journal of Physiology - Renal Physiology*, **2012**, 302, F647-57	4.3	120
153	Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. *American Journal of Kidney Diseases*, **1999**, 33, 458-63	7.4	119
152	Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 2119-26	12.7	104
151	Reduced Klotho is associated with the presence and severity of coronary artery disease. *Heart*, **2014**, 100, 34-40	5.1	101
150	Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. *Nephrology Dialysis Transplantation*, **2006**, 21, 3428-34	4.3	101
149	Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. *Seminars in Dialysis*, **2009**, 22, 37-44	2.5	98
148	Vascular calcification in patients with nondialysis CKD over 3 years. *Clinical Journal of the American Society of Nephrology: CJASN*, **2015**, 10, 654-66	6.9	93
147	Diabetic kidney disease: from physiology to therapeutics. *Journal of Physiology*, **2014**, 592, 3997-4012	3.9	86

146	Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. *Kidney International*, **2005**, S98-102	9.9	83
145	Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. *Nephrology Dialysis Transplantation*, **2014**, 29, 282-9	4.3	81
144	Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients. *American Journal of Kidney Diseases*, **1999**, 34, 43-8	7.4	80
143	Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. *Scientific World Journal, The*, **2006**, 6, 908-17	2.2	79
142	Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. *World Journal of Diabetes*, **2012**, 3, 7-18	4.7	76
141	Inflammation in diabetic kidney disease. *World Journal of Diabetes*, **2014**, 5, 431-43	4.7	73
140	The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years. *Journal of Clinical Medicine*, **2015**, 4, 1207-16	5.1	73
139	Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. *American Journal of Nephrology*, **1996**, 16, 95-7	4.6	72
138	Expression of FGF23/KLOTHO system in human vascular tissue. *International Journal of Cardiology*, **2013**, 165, 179-83	3.2	71
137	Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2011**, 6, 2272-9	6.9	69
136	Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. *Nephrology Dialysis Transplantation*, **2015**, 30, 1176-85	4.3	66
135	Inflammation in Diabetic Kidney Disease. *Nephron*, **2019**, 143, 12-16	3.3	65
134	Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 1646-54	6.9	63
133	Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. *Cytokine and Growth Factor Reviews*, **2009**, 20, 165-73	17.9	60
132	Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 182, 1004-10	10.2	59
131	Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study. *BMC Nephrology*, **2011**, 12, 53	2.7	54
130	Amino acid losses during hemodialysis with polyacrylonitrile membranes: effect of intradialytic amino acid supplementation on plasma amino acid concentrations and nutritional variables in nondiabetic patients. *American Journal of Clinical Nutrition*, **2000**, 71, 765-73	7	54
129	Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. *American Journal of Kidney Diseases*, **2003**, 42, 264-70	7.4	52

128	Randomized prospective comparison between erythropoietin and androgens in CAPD patients. *Kidney International*, **2002**, 61, 1537-44	9.9	50
127	Dietary Quality and Adherence to Dietary Recommendations in Patients Undergoing Hemodialysis. *Journal of Renal Nutrition*, **2016**, 26, 190-5	3	48
126	Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients. *Nephrology Dialysis Transplantation*, **2008**, 23, 919-26	4.3	48
125	Inflammatory Targets in Diabetic Nephropathy. *Journal of Clinical Medicine*, **2020**, 9,	5.1	46
124	Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade. *Journal of Clinical Medicine*, **2015**, 4, 1325-47	5.1	44
123	Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. *American Journal of Kidney Diseases*, **1996**, 27, 431-4	7.4	44
122	Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results. *Journal of Diabetes and Its Complications*, **2011**, 25, 314-9	3.2	38
121	Effect of proinflammatory cytokines (IL-6, TNF-alpha, IL-1beta) on hemodynamic performance during orthotopic liver transplantation. *Transplantation Proceedings*, **2003**, 35, 1884-7	1.1	37
120	Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease. *Diabetes Care*, **2018**, 41, 1817-1820	14.6	36
119	The role of inflammation as a pathogenic factor in the development of renal disease in diabetes. *Current Diabetes Reports*, **2005**, 5, 399-401	5.6	36
118	Implications of Klotho in vascular health and disease. *World Journal of Cardiology*, **2014**, 6, 1262-9	2.1	36
117	Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension. *Journal of Hypertension*, **2008**, 26, 2168-75	1.9	34
116	Serum magnesium concentration and PTH levels. Is long-term chronic hypermagnesemia a risk factor for adynamic bone disease?. *Scandinavian Journal of Urology and Nephrology*, **1997**, 31, 275-80		31
115	Inflammation and pathogenesis of diabetic nephropathy. *Metabolism: Clinical and Experimental*, **2004**, 53, 265-6; author reply 266-7	12.7	31
114	FGF23/Klotho axis: phosphorus, mineral metabolism and beyond. *Cytokine and Growth Factor Reviews*, **2012**, 23, 37-46	17.9	30
113	Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing low-density lipoprotein apheresis by dextran sulfate adsorption. *Metabolism: Clinical and Experimental*, **1995**, 44, 929-33	12.7	28
112	Influence of Klotho gene polymorphisms on vascular gene expression and its relationship to cardiovascular disease. *Journal of Cellular and Molecular Medicine*, **2016**, 20, 128-33	5.6	28
111	GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. *Journal of Clinical Medicine*, **2020**, 9,	5.1	27

110	Standards for ultrasound guidance of suprapubic bladder aspiration. *Pediatric Nephrology*, **1997**, 11, 607-9	3.2	26
109	Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons. *Journal of Clinical Medicine*, **2019**, 8,	5.1	25
108	Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients. *American Journal of Nephrology*, **1996**, 16, 268-72	4.6	25
107	Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. *Scandinavian Journal of Urology and Nephrology*, **1999**, 33, 121-5		24
106	Soluble levels and endogenous vascular gene expression of are related to inflammation in human atherosclerotic disease. *Clinical Science*, **2017**, 131, 2601-2609	6.5	23
105	Efficacy of molecular adsorbent recirculating system for the treatment of intractable pruritus in cholestasis. *American Journal of Medicine*, **2003**, 114, 62-4	2.4	23
104	Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?. *CKJ: Clinical Kidney Journal*, **2019**, 12, 313-321	4.5	22
103	Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study. *Journal of Clinical Pharmacology*, **2013**, 53, 421-6	2.9	22
102	Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study. *Nephrology Dialysis Transplantation*, **2017**, 32, 513-520	4.3	22
101	Cerivastatin-induced rhabdomyolysis. *Annals of Internal Medicine*, **2000**, 132, 598	8	21
100	Serum and gene expression profile of tumor necrosis factor-alpha and interleukin-6 in hypertensive diabetic patients: effect of amlodipine administration. *International Journal of Immunopathology and Pharmacology*, **2010**, 23, 51-9	3	20
99	Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease. *Atherosclerosis*, **2015**, 242, 37-44	3.1	19
98	Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes. *Cytokine and Growth Factor Reviews*, **2016**, 28, 71-7	17.9	19
97	Cardiac tamponade as presentation of systemic amyloidosis. *International Journal of Cardiology*, **1992**, 36, 107-8	3.2	19
96	Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?. *Journal of Clinical Medicine*, **2020**, 9,	5.1	17
95	Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease. *Mediators of Inflammation*, **2014**, 2014, 670475	4.3	17
94	What is the optimal level of vitamin D in non-dialysis chronic kidney disease population?. *World Journal of Nephrology*, **2016**, 5, 471-81	3.6	17
93	Relationship between inflammation and microalbuminuria in prehypertension. *Journal of Human Hypertension*, **2013**, 27, 119-25	2.6	16

92	Effect of different membranes on amino-acid losses during haemodialysis. *Nephrology Dialysis Transplantation*, **1998**, 13, 113-7	4.3	16
91	Improvement of erythropoietin-induced hypertension in hemodialysis patients changing the administration route. *Scandinavian Journal of Urology and Nephrology*, **1995**, 29, 11-4		16
90	Anti-neutrophil cytoplasmic antibody-associated paraneoplastic vasculitis. *Postgraduate Medical Journal*, **1994**, 70, 373-5	2	16
89	Pathophysiological implications of fibroblast growth factor-23 and Klotho and their potential role as clinical biomarkers. *Clinical Chemistry*, **2014**, 60, 933-40	5.5	15
88	Klotho in cardiovascular disease: Current and future perspectives. *World Journal of Biological Chemistry*, **2015**, 6, 351-7	3.8	15
87	Erdheim-Chester disease as cause of end-stage renal failure: a case report and review of the literature. *International Urology and Nephrology*, **2010**, 42, 1107-12	2.3	15
86	Phenotypic Modulation of Cultured Primary Human Aortic Vascular Smooth Muscle Cells by Uremic Serum. *Frontiers in Physiology*, **2018**, 9, 89	4.6	14
85	Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. *Nephrology Dialysis Transplantation*, **2020**, 35, i13-i23	4.3	13
84	Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?. *Journal of Clinical Medicine*, **2015**, 4, 1866-89	5.1	13
83	Inflammatory pathways. *Contributions To Nephrology*, **2011**, 170, 113-123	1.6	13
82	Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 4180-4	5.9	11
81	Recurrent severe acute hepatitis and omeprazole. *Annals of Internal Medicine*, **1997**, 127, 1135-6	8	11
80	Bone loss in children with idiopathic hypercalciuria. *Nephron*, **1998**, 78, 341-2	3.3	11
79	Association between serum levels of Klotho and inflammatory cytokines in cardiovascular disease: a case-control study. *Aging*, **2020**, 12, 1952-1964	5.6	11
78	Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients. *Transplantation*, **2016**, 100, 2432-2438	1.8	10
77	ENaC modulators and renal disease. *Current Molecular Pharmacology*, **2013**, 6, 35-43	3.7	10
76	Infectious spondylodiscitis in hemodialysis. *Seminars in Dialysis*, **2010**, 23, 619-26	2.5	10
75	Cerivastatin-induced rhabdomyolysis in a renal transplant on cyclosporin. *Transplantation*, **2001**, 72, 551	1.8	10

74	Identification of permissive insertion sites for generating functional fluorescent mineralocorticoid receptors. *Endocrinology*, **2012**, 153, 3517-25	4.8	9
73	Hypercalciuria in pediatric patients with ureteropelvic junction obstruction is of genetic origin. *Scandinavian Journal of Urology and Nephrology*, **2007**, 41, 144-8		9
72	Androgen therapy for anemia in elderly uremic patients. *International Urology and Nephrology*, **2001**, 32, 549-57	2.3	9
71	Serum magnesium and parathyroid hormone levels in dialysis patients. *Kidney International*, **2000**, 57, 2654	9.9	9
70	Control of severe proteinuria with losartan after renal transplantation. *American Journal of Nephrology*, **1998**, 18, 261-2	4.6	9
69	Influence of body iron stores on the serum erythropoietin concentration in hemodialyzed patients. *American Journal of Nephrology*, **1994**, 14, 95-8	4.6	8
68	Fibroblast growth factor 23 expression in human calcified vascular tissues. *Aging*, **2019**, 11, 7899-7913	5.6	8
67	Serum urate is related to subclinical inflammation in asymptomatic hyperuricaemia. *Rheumatology*, **2021**, 60, 371-379	3.9	8
66	Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications. *Frontiers in Medicine*, **2020**, 7, 628289	4.9	8
65	Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study. *BMC Nephrology*, **2012**, 13, 60	2.7	7
64	Effects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients. *Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis*, **1997**, 13, 257-9		7
63	Androgens for the treatment of anemia in peritoneal dialysis patients. *Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis*, **1998**, 14, 232-5		7
62	Idiopathic acute interstitial nephritis and uveitis associated with deafness. *Nephrology Dialysis Transplantation*, **1997**, 12, 781-4	4.3	6
61	Errors in the selection of dialysate concentrates cause severe metabolic acidosis during bicarbonate hemodialysis. *Artificial Organs*, **1997**, 21, 966-8	2.6	6
60	Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease. *Current Drug Targets*, **2014**, 15, 703-9	3	6
59	FGF23 and Klotho Levels are Independently Associated with Diabetic Foot Syndrome in Type 2 Diabetes Mellitus. *Journal of Clinical Medicine*, **2019**, 8,	5.1	5
58	ERBP guideline on management of patients with diabetes and chronic kidney disease stage 3B or higher. Metformin for all?. *Nefrologia*, **2017**, 37, 567-571	0.4	5
57	Best blood sample draw site during liver transplantation. *Transplantation Proceedings*, **2009**, 41, 991-3	1.1	5

56	Negative effect of angiotensin-converting enzyme inhibitors on erythropoietin response in CAPD patients. *American Journal of Nephrology*, **2000**, 20, 248	4.6	5
55	IgM antibodies to hepatitis C virus and haemodialysis patients. *Nephrology Dialysis Transplantation*, **1994**, 9, 1211	4.3	5
54	Increased SGK1 activity potentiates mineralocorticoid/NaCl-induced kidney injury. *American Journal of Physiology - Renal Physiology*, **2021**, 320, F628-F643	4.3	5
53	Pharmacological interactions of phosphate binders. *Nefrologia*, **2018**, 38, 573-578	0.4	5
52	Cytokines in Diabetes and Diabetic Complications **2017**, 119-128		4
51	Association of the rs495392 Klotho polymorphism with atheromatosis progression in patients with chronic kidney disease. *Nephrology Dialysis Transplantation*, **2019**, 34, 2079-2088	4.3	4
50	Low-density lipoprotein apheresis in homozygous familial hypercholesterolemia. *American Journal of Cardiology*, **2001**, 88, 202-3	3	4
49	Effect of angiotensin-converting enzyme inhibitors on hematological parameters and recombinant human erythropoietin doses in peritoneal dialysis patients. *Nephron*, **1998**, 80, 239	3.3	4
48	Acute cardiovascular effects of intravenous cyclosporine. *International Urology and Nephrology*, **1996**, 28, 575-81	2.3	4
47	Magnesium in Chronic Renal Failure **2007**, 303-315		4
46	Prevalence of Vertebral Fractures and Their Prognostic Significance in the Survival in Patients with Chronic Kidney Disease Stages 3-5 Not on Dialysis. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
45	Bases para la creaci de las unidades cl icas cardiorrenales. Documento de consenso de los grupos de trabajo cardiorrenal de la SEC y la SEN. *REC: CardioClinics*, **2021**, 56, 284-284	0.2	3
44	Relationship between serum parathyroid hormone levels and lipid profile in hemodialysis patients. Evolution of lipid parameters after parathyroidectomy. *Clinical Nephrology*, **1998**, 49, 303-7	2.1	3
43	Anti-inflammatory profile of paricalcitol in kidney transplant recipients. *Nefrologia*, **2017**, 37, 622-629	1.5	2
42	Hemodialysis urea rebound and membrane biocompatibility: accuracy of Kt/V estimations. *Artificial Organs*, **1997**, 21, 91-5	2.6	2
41	Renal failure, anaemia, cytokines and inflammation. *Nephrology Dialysis Transplantation*, **2001**, 16, 1524-5	4.3	2
40	[Interleukin-17A: Possible mediator and therapeutic target in hypertension]. *Nefrologia*, **2021**, 41, 244-257	1.5	2
39	Pathophysiological Implications of Imbalances in Fibroblast Growth Factor 23 in the Development of Diabetes. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2

38	Urinary Clara Cell Protein in Kidney Transplant Patients: A Preliminary Study. *Transplantation Proceedings*, **2016**, 48, 2884-2887	1.1	2
37	Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study. *CKJ: Clinical Kidney Journal*, **2021**, 14, 681-687	4.5	2
36	Klotho as a biomarker of subclinical atherosclerosis in patients with moderate to severe chronic kidney disease. *Scientific Reports*, **2021**, 11, 15877	4.9	2
35	Will the new hypoglycaemic agents be effective on renal and cardiovascular protection in diabetes and renal diabetic disease?. *Nefrologia*, **2019**, 39, 3-10	0.4	1
34	A Novel Heterozygous Deletion Variant in Gene Leading to Haploinsufficiency and Impairment of Fibroblast Growth Factor 23 Signaling Pathway. *Journal of Clinical Medicine*, **2019**, 8,	5.1	1
33	Anti-inflammatory profile of paricalcitol in kidney transplant recipients. *Nefrologia*, **2017**, 37, 622-629	0.4	1
32	Lanthanum Carbonate Modulates Inflammatory Profile in Hemodialysis Patients: Relationship with Fibroblast Growth Factor-23. *European Journal of Inflammation*, **2013**, 11, 75-86	0.3	1
31	Association between anatomopathologic graft disorders during reperfusion and vena cava sIL-2r in orthotopic liver transplantation. *Transplantation Proceedings*, **2003**, 35, 1880-3	1.1	1
30	First experience in Spain with MARS in three patients with advanced liver failure. *Zeitschrift Fur Gastroenterologie*, **2001**, 39 Suppl 2, 20-1	1.6	1
29	Autosomal dominant polycystic kidney disease associated with familial sensorineural deafness. *Scandinavian Journal of Urology and Nephrology*, **1999**, 33, 63-5		1
28	Hepatitis B vaccine, hepatitis C virus infection, and haemodialysis. *Lancet, The*, **1995**, 346, 845	40	1
27	Chinese herbs can themselves be harmful: comment on the article by Gertner et al. *Arthritis and Rheumatism*, **1996**, 39, 354-5		1
26	Kv1.3 Channel Inhibition Limits Uremia-Induced Calcification in Mouse and Human Vascular Smooth Muscle.. *Function*, **2021**, 2, zqaa036	6.1	1
25	Interleukin-17A: Potential mediator and therapeutic target in hypertension. *Nefrologia*, **2021**, 41, 244-257	0.4	1
24	Osteoporosis in chronic kidney disease: A essential challenge. *Medicina Clínica*, **2021**, 158, 27-27	1	1
23	Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics. *Nutrients*, **2021**, 13,	6.7	1
22	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. *Nefrologia*, **2021**, 41, 391-402	1.5	1
21	Extracellular water/total body water ratio as predictor of mortality in hemodialysis patients. *Renal Failure*, **2021**, 43, 821-829	2.9	1

20	The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure: Position paper from the Cardiorenal Working Groups of the Spanish Society of Nephrology and the Spanish Society of Cardiology.. *CKJ: Clinical Kidney Journal*, **2022**, 15, 865-872	4.5	1
19	Klotho expression in peripheral blood circulating cells is associated with vascular and systemic inflammation in atherosclerotic vascular disease.. *Scientific Reports*, **2022**, 12, 8422	4.9	1
18	Urinary Dickkopf-3: a new biomarker for CKD progression and mortality. *Nephrology Dialysis Transplantation*, **2021**, 36, 2199-2207	4.3	0
17	SP812VITAMIN D RECEPTOR ACTIVATION REDUCES KLOTHO PROMOTER METHYLATION. *Nephrology Dialysis Transplantation*, **2017**, 32, iii416-iii416	4.3	
16	FP389DOES VELPHORO (SUCROFERRIC OXYHYDROXIDE) RESOLVE THE PROBLEM OF NON-ADHERENCE TO PHOSPHATE BINDERS IN HEMODIALYSIS? :STRATEGIES OF USE. *Nephrology Dialysis Transplantation*, **2018**, 33, i165-i165	4.3	
15	Herpes simplex virus as a sentinel lesion for cytomegalovirus infection. *Nephrology Dialysis Transplantation*, **1997**, 12, 853	4.3	
14	Intradialytic amino acid supplementation. *Nephron*, **2002**, 90, 509	3.3	
13	Intradialytic cardiovascular stability with low calcium dialysate levels. *Nephron*, **1998**, 78, 120	3.3	
12	Diuretics, ACE inhibitors, and cardiac failure. *Lancet, The*, **1995**, 346, 700-1	40	
11	Long-term hospital support for dialysis. *Lancet, The*, **1995**, 346, 902	40	
10	Renal lymphoma and human immunodeficiency virus infection. *Mayo Clinic Proceedings*, **1995**, 70, 1224-5	6.4	
9	Hiatal hernia in predialysis patients. *Nephrology Dialysis Transplantation*, **1996**, 11, 2370	4.3	
8	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. *Nefrologia*, **2021**, 41, 391-402	0.4	
7	Mineralocortidoid Receptor Mediates Uremic Serum-Induced Increase in Endothelial Cell Dysfunction. *FASEB Journal*, **2018**, 32, 904.8	0.9	
6	The role of Mineralocorticoid Receptor on Human Aortic Endothelial Ion Channel Expression Profile in Chronic Kidney Disease. *FASEB Journal*, **2015**, 29, 844.19	0.9	
5	New information on phosphate binder interactions with vitamin K. *Nefrologia*, **2020**, 40, 369-370	0.4	
4	817-P: Inside CKD: Modeling the Direct Economic Burden of Concomitant Chronic Kidney Disease and Type 2 Diabetes. *Diabetes*, **2021**, 70, 817-P	0.9	
3	Vitamin D and Inflammation in Chronic Kidney Disease **2016**, 305-319		

2	FP612PROSPECTIVE REAL-WORLD DATA WITH SUCROFERRIC OXYHYDROXIDE IN HEMODIALYSIS PATIENTS: EFFECTS ON MINERAL, IRON AND INFLAMMATORY PROFILE. *Nephrology Dialysis Transplantation*, **2018**, 33, i248-i248	4.3
1	Activation of vitamin D receptors in the optimization of hyperparathyroidism secondary to dialysis. *Nefrologia*, **2013**, 33, 571-84	1.5